The Multiple Myeloma Research Consortium (MMRC) was founded in 2004 by Kathy Giusti, a multiple myeloma patient and Founder and CEO of the Multiple Myeloma Research Foundation (MMRF). The MMRC is the first collaborative research model of its kind that brings together academic and community cancer centers with industry to advance innovative phase 1 and phase 2 clinical trials of today’s most promising drug candidates.
Today, the MMRC leads a robust clinical network of 16 Member Institutions across the country that work together as one. MMRC Member Institutions are supported by an advanced infrastructure, including a cutting-edge Tissue Bank and IT systems that enable rapid, seamless collaboration.
To date, the MMRC has campaigned over 30 trials of more than 20 compounds and combinations across multiple drug classes. Eight drugs studied in MMRC clinical trials have since moved into phase 3 studies and two are awaiting marketing approval from the FDA. Driven by highly defined metrics that mandate accountability and strongly promote team science, MMRC began trials 60% faster and enrolled patients 10% faster than the industry standard.
“Working with the MMRF and the MMRC provides both the resources and the access to top-tier investigators and clinical trial sites that can be of tremendous help in accelerating the potential of novel therapies, such as ganetespib, to benefit patients with multiple myeloma.”
– Safi Bahcall, PhD, President and CEO, Synta Pharmaceuticals